Login

Journal Front Page

News & Events

  • April 2024 Issue delayed
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, Volume 13, Issue 2 (April 2024) Issue) schedule published on 15 April 2024 is delay due to some technical problem. It will published on 22 April 2024. Sorry for inconvenience. For other details You can vist the website http://www.ajper.com
  • Call for article for April 2024 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 March, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • January 2024 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 1 (January 2024) Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS DETERMINATION OF OMBITASVIR, PARITAPREVIR AND RITONAVIR IN TABLET DOSAGE FORMS

Jahnavi Bandla*1, S. Ganapaty2

1Department of Pharmaceutical Analysis and QA, Faculty of Pharmacy, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak-502313, Telangana, India.

2Department of Pharmacognosy and Phytochemistry, GITAM Institute of Pharmacy, GITAM University, Rushikonda, Visakhapatnam-530045, Andhra Pradesh, India

ABSTRACT

A specific, stability indicating method was developed and validated for the simultaneous estimation of Ombitasvir, Paritaprevir and Ritonavir in the pharmaceutical dosage form using RP-HPLC. The separation was done using BDS (250mm x 4.6mm, 5µ particle size) column with a mobile phase consisting of ammonium acetate buffer and acetonitrile in the ratio 40:60%v/v on isocratic mode. The mobile phase is pumped into the system at a flow rate of 1.0ml/min. The column oven temperature is maintained at 30ºC. The samples were detected at the wavelength of 257nm. The method was validated as per ICH guidelines. The method was found to be specific, accurate, precise, rugged and robust. The method obeys Beer’s law in the concentration range of 3.13µg/ml – 18.75µg/ml for Ombitasvir, 12.5µg/ml – 75µg/ml for Paritaprevir and 18.75µg/ml 112.5µg/ml for Ritonavir. The correlation coefficient was found to be 0.9996 for Ombitasvir, 0.9996 for Paritaprevir and 0.9997 for Ritonavir. Forced degradation studies were conducted for the standard drug solutions and found to be stable across various stressed conditions. The developed method can be used for the routine analysis of Ombitasvir, Paritaprevir and Ritonavir in pharmaceutical dosage form.

Keywords: Ombitasvir, Paritaprevir, Ritonavir, Stability indicating, Method development, Validation, RP-HPLC


[Full Text Article]